secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001654954-23-014015
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 4.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata Therapeutics appoints Moss Adams as auditor, reports $6.6M cash, advances DMT310 to Phase 3
--------------------------------------------------------------------------------

- Appointed Moss Adams LLP as new auditor for FY2023, effective Nov 9, 2023, replacing MHM.
- Cash and cash equivalents $6.6M as of Sep 30, 2023; expects to fund operations into Q2 2024.
- Received positive FDA feedback on End of Phase 2 meeting for DMT310; agreed Phase 3 program acceptable for NDA filing.
- Completed start-up activities for DMT310 Phase 3 STAR-1 trial; plans to initiate before end of 2023 after FDA protocol approval.
- Q3 2023 R&D expenses $0.9M (down from $1.6M YoY); G&A expenses flat at $0.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495423014015/0001654954-23-014015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495423014015/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-014015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer